Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Intellia Therapeutics (NASDAQ:NTLA) has announced two upcoming virtual investor events in November 2024. The first event, scheduled for November 7 at 8 a.m. ET, will present third quarter 2024 financial results and operational highlights. The second event, on November 16 at 11 a.m. CT/12 p.m. ET, will showcase new clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z), their investigational CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis. The nex-z data presentation follows a late-breaking oral presentation at the 2024 American Heart Association Scientific Sessions in Chicago. This therapy is being developed in collaboration with Regeneron as a single-dose treatment.
Intellia Therapeutics (NASDAQ:NTLA) ha annunciato due eventi virtuali per investitori in programma a novembre 2024. Il primo evento, fissato per il 7 novembre alle 8:00 ET, presenterà i risultati finanziari e le principali attività operative del terzo trimestre 2024. Il secondo evento, il 16 novembre alle 11:00 CT/12:00 ET, metterà in evidenza nuovi dati clinici dello studio di Fase 1 di nexiguran ziclumeran (nex-z), la loro terapia sperimentale di editing genetico basata su CRISPR per l'amiloidosi da transtiretina (ATTR). La presentazione dei dati su nex-z segue una presentazione orale di rilievo durante le Sessioni Scientifiche della American Heart Association 2024 a Chicago. Questa terapia è in fase di sviluppo in collaborazione con Regeneron come trattamento a dose singola.
Intellia Therapeutics (NASDAQ:NTLA) ha anunciado dos próximos eventos virtuales para inversores en noviembre de 2024. El primer evento, programado para el 7 de noviembre a las 8 a.m. ET, presentará los resultados financieros y los aspectos operativos del tercer trimestre de 2024. El segundo evento, el 16 de noviembre a las 11 a.m. CT/12 p.m. ET, mostrará nuevos datos clínicos del estudio de Fase 1 de nexiguran ziclumeran (nex-z), su terapia experimental de edición genética basada en CRISPR para la amiloidosis por transtiretina (ATTR). La presentación de datos de nex-z sigue a una presentación oral de última hora en las Sesiones Científicas de la American Heart Association 2024 en Chicago. Esta terapia se está desarrollando en colaboración con Regeneron como un tratamiento de dosis única.
인텔리아 테라퓨틱스(NASDAQ:NTLA)는 2024년 11월에 예정된 두 가지 가상 투자자 이벤트를 발표했습니다. 첫 번째 이벤트는 11월 7일 오전 8시 ET에 예정되어 있으며, 2024년 3분기 재무 결과와 운영 하이라이트를 발표할 것입니다. 두 번째 이벤트는 11월 16일 오전 11시 CT/오후 12시 ET에 열리며, nexiguran ziclumeran (nex-z), 그들의 CRISPR 기반 유전자 편집 치료법인 트랜스티레틴(ATTR) 아밀로이드증의 1상 연구에서 나온 새로운 임상 데이터를 선보일 것입니다. nex-z 데이터 발표는 2024년 시카고에서 열린 미국심장협회 과학 세션의 늦게 발표된 구두 발표에 이어 진행됩니다. 이 치료법은 Regeneron과 협력하여 단일 투여 요법으로 개발되고 있습니다.
Intellia Therapeutics (NASDAQ:NTLA) a annoncé deux événements virtuels à venir pour les investisseurs en novembre 2024. Le premier événement, prévu le 7 novembre à 8h00 ET, présentera les résultats financiers et les points forts opérationnels du troisième trimestre 2024. Le deuxième événement, le 16 novembre à 11h00 CT/12h00 ET, mettra en avant de nouvelles données cliniques de l'étude de Phase 1 de nexiguran ziclumeran (nex-z), leur thérapie expérimentale d'édition génétique basée sur CRISPR pour l'amyloïdose à transtyretine (ATTR). La présentation des données sur nex-z fait suite à une présentation orale tardive lors des Sessions Scientifiques de la American Heart Association 2024 à Chicago. Cette thérapie est en cours de développement en collaboration avec Regeneron comme traitement à dose unique.
Intellia Therapeutics (NASDAQ:NTLA) hat zwei bevorstehende virtuelle Investorenveranstaltungen im November 2024 angekündigt. Die erste Veranstaltung, die am 7. November um 8 Uhr ET stattfinden soll, wird die finanziellen Ergebnisse und operativen Highlights des dritten Quartals 2024 präsentieren. Die zweite Veranstaltung, die am 16. November um 11 Uhr CT/12 Uhr ET geplant ist, wird neue klinische Daten aus der Phase-1-Studie von nexiguran ziclumeran (nex-z), ihrer experimentellen CRISPR-basierten Gentherapie für transthyretin (ATTR) Amyloidose, vorstellen. Die Präsentation der nex-z-Daten folgt einem späten mündlichen Vortrag während der wissenschaftlichen Sitzungen der American Heart Association 2024 in Chicago. Diese Therapie wird in Zusammenarbeit mit Regeneron als einmalige Behandlung entwickelt.
- None.
- None.
- Third quarter 2024 financial results – November 7, at 8 a.m. ET
- New clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November.
Third Quarter 2024 Earnings – November 7, at 8 a.m. ET
Intellia will present its third quarter 2024 financial results and operational highlights.
- To join the call, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726 approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
Clinical Data Update from Phase 1 Study of nex-z – November 16, at 11 a.m. CT / 12 p.m. ET
Intellia will also host an investor webcast to review new data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001), following a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16-18 in Chicago, Illinois. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron.
- To join the webcast, please visit this link, or the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com.
A replay of the events will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com for at least 30 days following the event.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
+1-917-640-7930
media@intelliatx.com
mcrenson@tenbridgecommunications.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Intellia Therapeutics (NTLA) release Q3 2024 earnings?
What is the purpose of Intellia's November 16, 2024 investor event?
What is nexiguran ziclumeran (nex-z) being developed for by Intellia (NTLA)?
Who is Intellia collaborating with on the development of nex-z (NTLA-2001)?
